Literature DB >> 15606624

Enhanced interleukin-18 levels in the peripheral blood of children with coeliac disease.

H Lettesjö1, T Hansson, A Bergqvist, J Grönlund, A Dannaeus.   

Abstract

Coeliac disease (CoD) is a small intestinal disorder characterized by villous atrophy, crypt cell hyperplasia and an increased production of T helper cell type 1 (Th1) cytokines. Interleukin (IL)-18 is a pro-inflammatory cytokine that has a crucial role in maintaining the Th1 response. In this study, the serum levels of IL-18 were measured in children with CoD or other gastrointestinal diseases in order to evaluate the possibility of using IL-18 as a disease activity marker. IL-18 levels were higher in samples from CoD patients [median 443 pg/ml (148-885)] compared to healthy controls [median 205 pg/ml (11-379)], P <0.05. In contrast, the levels of IL-18 were not enhanced significantly in the serum from patients with inflammatory bowel disease (IBD) [median 324 pg/ml (207-546)] or in the disease control group [median 303 pg/ml (2-689)]. In CoD patients, after 2 weeks of gluten challenge (GC), serum IL-18 was unchanged [median 268 pg/ml (59-458)] compared to patients on a gluten-free diet [median 220 pg/ml (53-600)], while IL-18 was increased after 12 weeks of GC [median 551 pg/ml (94-952)], P <0.01. The IL-18 levels correlated with IgA anti-transglutaminase antibody levels (rs=0.59, P=0.016) in serum from untreated CoD patients, and IL-18 also followed the degree of small intestinal villous atrophy in 12 out of 19 CoD patients. Our results support the view that serum IL-18 concentrations in children with CoD follow disease activity, suggesting a role for IL-18 in the induction of an inflammatory Th1-response after gluten exposure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15606624      PMCID: PMC1809275          DOI: 10.1111/j.1365-2249.2005.02661.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

Review 1.  IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family.

Authors:  C A Dinarello
Journal:  J Allergy Clin Immunol       Date:  1999-01       Impact factor: 10.793

2.  Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease.

Authors:  O Molberg; S N Mcadam; R Körner; H Quarsten; C Kristiansen; L Madsen; L Fugger; H Scott; O Norén; P Roepstorff; K E Lundin; H Sjöström; L M Sollid
Journal:  Nat Med       Date:  1998-06       Impact factor: 53.440

Review 3.  Regulation of interferon-gamma production by IL-12 and IL-18.

Authors:  H Okamura; S Kashiwamura; H Tsutsui; T Yoshimoto; K Nakanishi
Journal:  Curr Opin Immunol       Date:  1998-06       Impact factor: 7.486

4.  Production of antibodies to gliadin by peripheral blood lymphocytes in children with celiac disease: the use of an enzyme-linked immunospot technique for screening and follow-up.

Authors:  T Hansson; A Dannaeus; W Kraaz; O Sjöberg; L Klareskog
Journal:  Pediatr Res       Date:  1997-04       Impact factor: 3.756

5.  Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme.

Authors:  Y Gu; K Kuida; H Tsutsui; G Ku; K Hsiao; M A Fleming; N Hayashi; K Higashino; H Okamura; K Nakanishi; M Kurimoto; T Tanimoto; R A Flavell; V Sato; M W Harding; D J Livingston; M S Su
Journal:  Science       Date:  1997-01-10       Impact factor: 47.728

6.  Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity.

Authors:  Y van de Wal; Y Kooy; P van Veelen; S Peña; L Mearin; G Papadopoulos; F Koning
Journal:  J Immunol       Date:  1998-08-15       Impact factor: 5.422

7.  Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with celiac disease.

Authors:  E M Nilsen; F L Jahnsen; K E Lundin; F E Johansen; O Fausa; L M Sollid; J Jahnsen; H Scott; P Brandtzaeg
Journal:  Gastroenterology       Date:  1998-09       Impact factor: 22.682

8.  Autoantibodies to tissue transglutaminase as predictors of celiac disease.

Authors:  W Dieterich; E Laag; H Schöpper; U Volta; A Ferguson; H Gillett; E O Riecken; D Schuppan
Journal:  Gastroenterology       Date:  1998-12       Impact factor: 22.682

9.  Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma.

Authors:  E M Nilsen; K E Lundin; P Krajci; H Scott; L M Sollid; P Brandtzaeg
Journal:  Gut       Date:  1995-12       Impact factor: 23.059

10.  Expression of tumour necrosis factor-alpha, interleukin-6, and interleukin-2 mRNA in the jejunum of patients with coeliac disease.

Authors:  M Kontakou; R T Przemioslo; R P Sturgess; A G Limb; P J Ciclitira
Journal:  Scand J Gastroenterol       Date:  1995-05       Impact factor: 2.423

View more
  5 in total

1.  The chemokine CCL28 is elevated in the serum of patients with celiac disease and decreased after treatment.

Authors:  Shima Rashidiani; Ali Jalili; Erfan Babaei; Farsad Sheikhesmaeili; Shohreh Fakhari; Pedram Ataee; Baran Parhizkar
Journal:  Am J Clin Exp Immunol       Date:  2017-06-15

2.  Interleukin-18 binding protein in the sera of patients with Wegener's granulomatosis.

Authors:  D Novick; D Elbirt; C A Dinarello; M Rubinstein; Z M Sthoeger
Journal:  J Clin Immunol       Date:  2008-07-02       Impact factor: 8.317

3.  No difference in markers of adipose tissue inflammation between overweight women with polycystic ovary syndrome and weight-matched controls.

Authors:  Asa Lindholm; Caroline Blomquist; Marie Bixo; Ingrid Dahlbom; Tony Hansson; Inger Sundström Poromaa; Jonas Burén
Journal:  Hum Reprod       Date:  2011-04-08       Impact factor: 6.918

4.  Association study of functional genetic variants of innate immunity related genes in celiac disease.

Authors:  B Rueda; A Zhernakova; M A López-Nevot; J Martín; B P C Koeleman
Journal:  BMC Med Genet       Date:  2005-08-03       Impact factor: 2.103

5.  Serum cytokine pattern in young children with screening detected coeliac disease.

Authors:  S Björck; S R Lindehammer; M Fex; D Agardh
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.